Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Deferred Revenue: 2023-2025

Historic Current Deferred Revenue for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $37,915.

  • bioAffinity Technologies' Current Deferred Revenue rose 55.36% to $37,915 in Q3 2025 from the same period last year, while for Sep 2025 it was $37,915, marking a year-over-year increase of 55.36%. This contributed to the annual value of $24,404 for FY2024, which is 26.18% down from last year.
  • Per bioAffinity Technologies' latest filing, its Current Deferred Revenue stood at $37,915 for Q3 2025, which was up 55.36% from $24,404 recorded in Q2 2025.
  • bioAffinity Technologies' Current Deferred Revenue's 5-year high stood at $43,000 during Q2 2023, with a 5-year trough of $24,404 in Q3 2024.
  • In the last 3 years, bioAffinity Technologies' Current Deferred Revenue had a median value of $28,154 in 2024 and averaged $30,615.
  • In the last 5 years, bioAffinity Technologies' Current Deferred Revenue crashed by 39.22% in 2024 and then skyrocketed by 55.36% in 2025.
  • bioAffinity Technologies' Current Deferred Revenue (Quarterly) stood at $33,058 in 2023, then fell by 26.18% to $24,404 in 2024, then soared by 55.36% to $37,915 in 2025.
  • Its Current Deferred Revenue stands at $37,915 for Q3 2025, versus $24,404 for Q2 2025 and $24,404 for Q1 2025.